[{"NetIncomeLoss_2_Q2_USD":-2286000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OperatingLeaseRightOfUseAsset_0_Q2_USD":45000.0,"ShareBasedCompensation_2_Q2_USD":522000.0,"Assets_0_Q2_USD":25498000.0,"CommonStockSharesIssued_0_Q2_shares":24919333.0,"AssetsCurrent_0_Q2_USD":25440000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":360000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":755000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":346000.0,"GainLossOnSaleOfPropertyPlantEquipment_1_Q2_USD":246000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"InterestAndOtherIncome_2_Q2_USD":99000.0,"InterestAndOtherIncome_1_Q2_USD":27000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":24630000.0,"IncreaseDecreaseInOtherCurrentLiabilities_2_Q2_USD":5000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":24779000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":818000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"Liabilities_0_Q2_USD":1314000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":25254000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-37000.0,"OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_0_Q2_USD":50000.0,"OtherAssetsCurrent_0_Q2_USD":186000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":3849000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_2_Q2_USD":26000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":20000.0,"IncreaseDecreaseInOtherCurrentAssets_2_Q2_USD":-82000.0,"CommonStockValue_0_Q2_USD":25000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":1596000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockSharesAuthorized_0_Q2_shares":120000000.0,"OperatingIncomeLoss_1_Q2_USD":-1163000.0,"NetIncomeLoss_1_Q2_USD":-1136000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":13000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"LesseeOperatingLeaseDiscountRate_0_Q2_pure":0.055,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":24184000.0,"AdditionalPaidInCapital_0_Q2_USD":195032000.0,"AccountsPayableCurrent_0_Q2_USD":416000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":2173000.0,"LiabilitiesCurrent_0_Q2_USD":1314000.0,"ProceedsFromWarrantExercises_2_Q2_USD":3849000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-2036000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_2_Q2_USD":360000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_1_Q2_USD":260000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":878000.0,"CommonStockSharesOutstanding_0_Q2_shares":24919333.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-170873000.0,"StockholdersEquity_0_Q2_USD":24184000.0,"OperatingIncomeLoss_2_Q2_USD":-2385000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":25498000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":84000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":252000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-22000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":522000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":45000.0,"OperatingExpenses_1_Q2_USD":1163000.0,"OperatingExpenses_2_Q2_USD":2385000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.05,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.09,"OtherLiabilitiesCurrent_0_Q2_USD":14000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":892000.0,"OperatingLeasesFutureMinimumPaymentsDue_0_Q2_USD":45000.0,"Ticker":"SAVA","CIK":"1069530","name":"CASSAVA SCIENCES INC","OfficialName":"Cassava Sciences Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"898902969.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200812"}]